PACIFIC SOFTWARE (PFSF) Stock Price, News & Analysis

Pacific Software Inc (OTC: PFSF) is a publicly quoted company whose business focus has evolved over time across several sectors, including restaurant development, skincare and aesthetics, dietary supplements, and, more recently, neuromedicine through a completed acquisition.

According to earlier disclosures, Pacific Software, Inc. operated through subsidiaries and joint ventures as an owner, partner, and investor in the restaurant business in the United States. The company described itself as organized to develop new restaurants and incubate promising brands, with a portfolio that included fast-casual and family-style concepts such as The Gallo Group of restaurants, a World of Beer franchise tavern, and The Good Wurst chain. Prior communications also noted a strategy focused on acquiring mini and medium-sized fast casual and casual restaurant chains throughout the United States.

More recent announcements describe a significant shift toward health, skincare, and neuromedicine. Pacific Software has been characterized as an emerging skincare and aesthetics company known for its patented cosmeceutical technology Dermatrix and science-based dietary supplements. Through an asset acquisition from Dreamaderm Inc., the company became the exclusive holder of a patented cosmeceutical asset branded as Dermatrix, a technology described as boosting natural collagen production by preserving insulin within the skin via inhibition of insulin-degrading enzyme (IDE). The company has highlighted the potential of Dermatrix for dermatological applications in cosmetics, wound healing, and advanced medical aesthetics procedures.

In addition to skincare, Pacific Software announced the acquisition of a science-based dietary supplement supporting brain health and memory function, sold under the brand names SuppleMEM AD™ and A.L.Z. Defense™. The core formula is described as a "medical food cocktail" composed of safe, natural products formulated to support aspects of memory such as neuroplasticity. The company reports that this formula was evaluated in two multi-year laboratory experiments funded by a grant from the National Institutes of Health, with studies conducted at the University of California, Irvine and the University of Kentucky in animal models of Alzheimer’s disease.

Pacific Software has indicated that acquiring this established product line represents an expansion of its business model from an exclusive focus on skin care and wound healing to a broader environment encompassing both health and skin care, while maintaining an emphasis on scientifically validated products. The company has described plans to manufacture the A.L.Z. Defense™ product in the United States and Mexico and to distribute it in both countries, with anticipated revenue through retail and wholesale channels, including online sales and established wholesale distribution networks.

The company’s relationship with academic and research institutions is a recurring theme in its communications. The Dermatrix technology is associated with research conducted over many years at institutions such as Harvard Medical School, The Scripps Research Institute, Mayo Clinic, and the University of California, Irvine, and the Regents of the University of California are identified as an equity stakeholder in Pacific Software in connection with the Dermatrix patent. The dietary supplement for memory health is linked to research funded by the National Institutes of Health and carried out by recognized Alzheimer’s researchers.

In the neuromedicine field, a subsequent announcement states that Pacific Software Inc. closed a transaction acquiring all outstanding shares of 10763942 Canada Inc. (dba PurMinds NeuroPharma, "PurMinds"). Following this transaction, the common stock is described as being quoted on the OTC market platform, with the PurMinds management team assuming leadership roles. The company has indicated that a corporate name change to PurMinds Enterprises is under consideration, pending approval by FINRA.

PurMinds NeuroPharma is described as a neuromedicine company developing solutions for neurological and psychiatric disorders through a precision medicine approach. Its business model is characterized in two parts: short- and mid-term revenue through exclusive development and distribution of precision diagnostic solutions based on SpectroChip’s photonic chip-based point-of-care testing (POCT) platform, and long-term value creation through novel therapeutics that promote neuroplasticity and modulate neuroinflammation. PurMinds reports a clinical pipeline that includes psychoactive compounds such as psilocybin and proprietary non-hallucinogenic small molecules, along with unique intellectual property assets, proprietary formulations, and partnerships with research and clinical institutions.

In connection with this neuromedicine focus, PurMinds has announced an exclusive global partnership with SpectroChip Inc. and SpectroChip Global Inc.. Under this agreement, PurMinds intends to integrate its precision neuromedicine research, including biomarker discovery and multi-omics studies, with SpectroChip’s photonic chip-based diagnostic technology to develop rapid, intelligent, and cost-effective point-of-care testing solutions. The goal described is to bring hospital-grade diagnostics with universal lateral flow immunoassay (LFIA) compatibility to the patient’s bedside and to support a "4P medicine" (predictive, preventive, personalized, and participatory) healthcare ecosystem.

Over time, Pacific Software’s public communications show a progression from restaurant development and brand incubation to dermatological cosmeceuticals, dietary supplements focused on brain health, and, through the PurMinds acquisition, precision neuromedicine and diagnostics. Investors reviewing the PFSF stock can therefore encounter information spanning multiple phases of the company’s evolution, from hospitality to health, skincare, and neuromedicine-related activities.

Business evolution and focus areas

Based on the available information, Pacific Software’s activities can be grouped into several focus areas that have appeared in its disclosures:

• Restaurant development and brand incubation: Ownership and joint ventures in fast-casual and family-style restaurant brands in the United States, including The Gallo Group, a World of Beer location, and The Good Wurst chain, as previously described.
• Dermatological cosmeceuticals: Exclusive rights to Dermatrix, a patented IDE-inhibiting cosmeceutical technology associated with collagen production, wound healing, and cosmetic applications.
• Dietary supplements for brain health: Acquisition of the SuppleMEM AD™ and A.L.Z. Defense™ product line, a science-based dietary supplement aimed at supporting brain health and memory function, with supporting laboratory research cited.
• Neuromedicine and precision diagnostics (via PurMinds): Development of precision neuromedicine therapeutics and diagnostics, including a partnership with SpectroChip to build photonic chip-based point-of-care testing platforms and a pipeline of psychoactive and non-hallucinogenic small molecule therapeutics.

Stock and corporate status

Pacific Software Inc. is identified in the provided materials as trading on the OTC market under the symbol PFSF. The company has disclosed corporate restructuring activities in prior years, including debt restructuring to improve its capital structure and balance sheet, and has discussed potential corporate name changes in connection with shifts in business strategy. The most recent news indicates that a name change to PurMinds Enterprises is being considered following the acquisition of PurMinds NeuroPharma, subject to regulatory approval.

Research and collaboration

The company’s communications emphasize collaborations and links with academic and research organizations. For Dermatrix, the underlying research is associated with work at Harvard Medical School, The Scripps Research Institute, Mayo Clinic, and the University of California, Irvine, and the Regents of the University of California are described as an equity stakeholder. For the memory-focused dietary supplement, the cited studies were funded by the National Institutes of Health and conducted at the University of California, Irvine and the University of Kentucky. In neuromedicine, PurMinds highlights partnerships with research and clinical institutions and an exclusive global partnership with SpectroChip for photonic chip-based diagnostics.